[go: up one dir, main page]

WO1997011666A3 - Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies - Google Patents

Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies Download PDF

Info

Publication number
WO1997011666A3
WO1997011666A3 PCT/IB1996/001059 IB9601059W WO9711666A3 WO 1997011666 A3 WO1997011666 A3 WO 1997011666A3 IB 9601059 W IB9601059 W IB 9601059W WO 9711666 A3 WO9711666 A3 WO 9711666A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
mercaptoethanolamine
mea
copper
prevention
Prior art date
Application number
PCT/IB1996/001059
Other languages
English (en)
Other versions
WO1997011666A2 (fr
Inventor
Samir Chachoua
Original Assignee
Samir Chachoua
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samir Chachoua filed Critical Samir Chachoua
Priority to JP9513260A priority Critical patent/JPH11514990A/ja
Priority to AU69990/96A priority patent/AU6999096A/en
Priority to EP96931214A priority patent/EP0858327A2/fr
Publication of WO1997011666A2 publication Critical patent/WO1997011666A2/fr
Publication of WO1997011666A3 publication Critical patent/WO1997011666A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne de nouvelles compositions et applications de 2-mercaptoéthanolamine (2-MEA) et d'aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (II). Ces compositions sont utilisées seules ou en association avec d'autres facteurs, agents ou procédés physiques, chimiques et/ou biologiques. Il peut s'agir de précurseurs, d'intermédiaires, de produits finis, de catalyseurs, de promoteurs et/ou d'autres facteurs, agents ou procédés mis en jeu directement ou indirectement depuis l'application initiale de la composition jusqu'à l'obtention du résultat recherché.
PCT/IB1996/001059 1995-09-25 1996-09-25 Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies WO1997011666A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP9513260A JPH11514990A (ja) 1995-09-25 1996-09-25 ２−メルカプトエタノールアミン（２−ｍｅａ）と類縁アミノチオール化合物および３，５−ジイソプロピルサリチル酸銅（▲ｉｉ▼）と類縁化合物の、各種疾患を予防および治療するための使用
AU69990/96A AU6999096A (en) 1995-09-25 1996-09-25 Use of 2-mercaptoethanolamine (2-mea) and related aminothiol compounds and copper(ii)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases
EP96931214A EP0858327A2 (fr) 1995-09-25 1996-09-25 Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US428195P 1995-09-25 1995-09-25
US60/004,281 1995-09-25

Publications (2)

Publication Number Publication Date
WO1997011666A2 WO1997011666A2 (fr) 1997-04-03
WO1997011666A3 true WO1997011666A3 (fr) 1997-06-19

Family

ID=21710013

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB1996/001059 WO1997011666A2 (fr) 1995-09-25 1996-09-25 Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies
PCT/IB1996/001115 WO1997011667A2 (fr) 1995-09-25 1996-09-25 Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB1996/001115 WO1997011667A2 (fr) 1995-09-25 1996-09-25 Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes

Country Status (5)

Country Link
EP (2) EP0858327A2 (fr)
JP (1) JPH11514990A (fr)
AU (2) AU7143196A (fr)
CA (2) CA2233015A1 (fr)
WO (2) WO1997011666A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6384259B1 (en) 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
PT1220678E (pt) * 1999-10-04 2007-06-11 John Carter Composições farmacêuticas contendo cobre, ácido salicílico e vitamina c
US7927612B2 (en) 2000-01-19 2011-04-19 Baofa Yu Combinations and methods for treating neoplasms
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US6506413B1 (en) * 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes
US7053072B2 (en) 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
FR2825923B1 (fr) * 2001-06-15 2006-04-07 Oreal Inhibiteur de no-synthase et utilisations
KR20030077743A (ko) * 2002-03-26 2003-10-04 변현규 In½
US7629333B2 (en) 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
AU2002353346A1 (en) * 2002-09-10 2004-04-30 Samir Chachoua Induced remission therapy
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US9125874B2 (en) 2007-11-30 2015-09-08 The Ramaekers Family Trust Administration of transfer factor for improving reproductive health
CN101138634A (zh) 2006-09-07 2008-03-12 于保法 用于治疗肿瘤的组合物
EP2278984A4 (fr) 2007-11-30 2013-02-27 Ramaekers Family Trust Compositions et procédés d'amélioration de la fertilité
US20110311557A1 (en) * 2009-02-11 2011-12-22 Martin Heath Bluth Reciprocal serum/plasma exchange for the treatment of cancer
SG11201704175WA (en) 2014-11-26 2017-06-29 Baofa Yu Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952607A (en) * 1982-05-27 1990-08-28 International Copper Research Association, Inc. Copper complex for treating cancer
US5488042A (en) * 1992-03-13 1996-01-30 Arch Development Corporation Method for protection against genotoxic mutagenesis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228127A (en) * 1978-10-06 1980-10-14 International Radioimmune Systems, Inc. Kit for detecting human chorionic gonadotropin
US5057314A (en) * 1988-09-30 1991-10-15 Whitfill Craig E Low molecular weight antiviral factors
US5310653A (en) * 1989-10-24 1994-05-10 Board Of Regents, The University Of Texas System Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis
DE4236069A1 (de) * 1992-10-26 1994-04-28 Werner Dr Bergmann Arzneimittel, insbesondere für orale Einnahme
WO1994028934A1 (fr) * 1993-06-07 1994-12-22 Center For Special Immunology Traitement adoptif de reconstitution immunitaire pour des patients atteints d'immunodeficiences acquises

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952607A (en) * 1982-05-27 1990-08-28 International Copper Research Association, Inc. Copper complex for treating cancer
US5488042A (en) * 1992-03-13 1996-01-30 Arch Development Corporation Method for protection against genotoxic mutagenesis

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANTICANCER RES., 1989, Vol. 9, CRISPENS et al., "Evaluation of Combinations of CuDIPS, Tween 80 and Cyclophosphamide as Therapy for Reticulum Cell Sarcoma in SJL/J Mice", pages 357-360. *
BIOCHEMICAL PHARMACOL., 1983, Vol. 32, No. 22, KENSLER et al., "Inhibition of Oxygen Radical Metabolism in Phorbol Ester-activated Polymorphonuclear Leukocytes by an Antitumor Promoting Copper Complex With Superoxide Dismutase-mimetic Activity", pages 3485-3487. *
BIOCHIM. BIOPHYS. ACTA., 1994, Vol. 1223, JEITNER et al., "Thiol-bearing Compounds Selectively Inhibit Protein Kinase C-dependent Oxidative Events and Proliferation of Human T Cells", pages 15-22. *
CARCINOGENESIS, 1988, Vol. 9, No. 4, REINERS et al., "Survey of Cytotoxicities and Antimutagenic and antitumor Initiating Activities of Cu(II)(3,5-diisopropylsalicylate)2 and its Analogs in a Keratinocyte-mediated Mutation Assay and the Murine Skin Multistage Carcinogenesis Model", pages 629-632. *
CHEMICAL ABSTRACTS, Vol. 85, No. 3, issued 19 July 1976 (Columbus, OH, USA), page 34, Abstract No. 13848n, GRAZIENE A., "Immunomorphalogical and Ultrastructural Study of Lymphoid Tissue During the Administration of D-penicillamine Under Experimental Autoimmune Conditions"; & VOPR. REVM., 1975, (4), 21-6 (Russ). *
CHEMICAL ABSTRACTS, Volume 99, No. 23, issued 05 December 1983, (Columbus, OH, USA), page 641, Abstract No. 193577u, TRYFIATES G.P., "Control of Tumor Growth by Pyridoxine Restriction of Treatment With an Antivitamin Agent"; & CANCER DETECT. PREV., 1981, 4(1-4), 159-64 (Eng.). *
J. CLIN. INVEST., May 1994, Vol. 93, BERGAMINI et al., "Cystamine Potently Suppresses In Vitro HIV Replication in Acutely and Chronically Infected Human Cells", pages 251-257. *

Also Published As

Publication number Publication date
EP0858327A2 (fr) 1998-08-19
CA2233445A1 (fr) 1997-04-03
WO1997011666A2 (fr) 1997-04-03
CA2233015A1 (fr) 1997-04-03
AU7143196A (en) 1997-04-17
WO1997011667A3 (fr) 1997-06-12
WO1997011667A2 (fr) 1997-04-03
JPH11514990A (ja) 1999-12-21
AU6999096A (en) 1997-04-17
EP0853486A2 (fr) 1998-07-22
EP0853486A4 (fr) 2001-09-26

Similar Documents

Publication Publication Date Title
WO1997011666A3 (fr) Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies
AU2639695A (en) Novel uses of triplex forming oligonucleotides for the treatment of human diseases
EP1029540A3 (fr) Utilisation de la droloxifène pour le traitement de maladies cardiovasculaires
ZA969820B (en) Fluorinated or hydroxylated phenylimidazolidines, preparation process and intermediates, use as medicaments, new use and pharmaceutical compositions.
HUT76258A (en) Compositions comprising dna damaging agents and p53, and methods for uses thereof
IL170120A (en) 4,2,1 - Triazines, their use in the preparation of HIV treatment or prophylaxis drugs, containing pharmaceutical preparations and methods for their preparation
BR9711194A (pt) Uso de agente quelante clioquinol para a fabricação de uma composição farmacêutica para o tratamento de doença de alzheimer.
HUP9800467A3 (en) Use of hyaluronic acid for producing pharmaceutical compns. for the treatment of interstitial cystitis
PL346904A1 (en) Pharmaceutical agents for the treatment of parkinson&#39;s disease, adhd and microadenomas
AU4069095A (en) Medicaments for the treatment of restenosis and arterial sclerosis
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer&#39;s disease.
WO1998059040A3 (fr) Sous-unite de telomerase catalytique humaine et son utilisation therapeutique et diagnostique
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
HU9600455D0 (en) Use of quinoxalines combined with protease-inhibiting compounds for producing pharmaceutical compositions for treating hiv infections
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
ZA962715B (en) Pharmaceutical agents for the treatment of Alzheimer&#39;s disease.
AU8851298A (en) L-threonate ferrous, as well as pharmaceutical composition and use for improvingand treating human anemia thereof
NL300083I1 (nl) 1-Beta-D-ribofuranosyl-1,2,4-triazool-3-carboxamide voor de bereiding van een geneesmiddel voor de medische behandeling van mensen.
AU7982098A (en) Use of beta2-adrenoceptor agonists for the manufacture of a medicament for the treatment of scoliosis
EP0755262A4 (fr) Composition de traitement de pneumopathie
SI0778025T1 (en) Use of 8,9-dehydroestrone for the manufacture of a medicament for the treatment of diseases caused by free radicals
DE59300883D1 (de) Verfahren zur Herstellung von Dianthrachinon-N,N&#39;-dihydroazin und dessen Chlorierungsprodukten.
FI961494L (fi) Farmaseuttisia koostumuksia ja niiden käyttö, etenkin hermoston rappeutumissairauksien hoitamiseksi
BR9507732A (pt) Composição farmacêutica para o tratamento de glaucoma
AU6819898A (en) Oxygen anion radicals and/or therapeutic preparations containing their reaction or breakdown products, and use of such preparations in the treatment of parkinson&#39;s disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU BB BG BR CA CN CU CZ EE FI GE HU IS JP KE KG KP KR LK LR LT LV MD MG MK MN MW MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU BB BG BR CA CN CU CZ EE FI GE HU IS JP KE KG KP KR LK LR LT LV MD MG MK MN MW MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2233445

Country of ref document: CA

Ref country code: CA

Ref document number: 2233445

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 513260

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996931214

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1996931214

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996931214

Country of ref document: EP